Clinical Trial: Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA

U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07620275) titled 'Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA' on May 27.

Brief Summary: KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r/r) multiple myeloma(MM) expressing CD19 and/or BCMA.

Study Start Date: June 10

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma

Intervention: BIOLOGICAL: KSVCBD injection

KSVCBD injection is an in vivo CAR-T therapy targe...